214 related articles for article (PubMed ID: 37108192)
1. Influence of Genetics on the Response to Omalizumab in Patients with Severe Uncontrolled Asthma with an Allergic Phenotype.
Rojo-Tolosa S; Sánchez-Martínez JA; Pineda-Lancheros LE; Gálvez-Navas JM; González-Gutiérrez MV; Jiménez-Gálvez G; Pérez-Ramírez C; Morales-García C; Jiménez-Morales A
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108192
[TBL] [Abstract][Full Text] [Related]
2. Retrospective Study on the Association of Biomarkers With Real-world Outcomes of Omalizumab-treated Patients With Allergic Asthma.
Kavati A; Zhdanava M; Ortiz B; Lecocq J; Schiffman B; Pilon D; Ho H; Lefebvre P; Stone B
Clin Ther; 2019 Oct; 41(10):1956-1971. PubMed ID: 31563391
[TBL] [Abstract][Full Text] [Related]
3. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation.
Norman G; Faria R; Paton F; Llewellyn A; Fox D; Palmer S; Clifton I; Paton J; Woolacott N; McKenna C
Health Technol Assess; 2013 Nov; 17(52):1-342. PubMed ID: 24267198
[TBL] [Abstract][Full Text] [Related]
4. Asthma control, lung function, symptoms, and corticosteroid sparing after omalizumab initiation in patients with allergic asthma.
Pilon D; Kavati A; Ortiz B; Paknis B; Vegesna A; Schiffman B; Zhdanava M; Lefebvre P; Stone B
Allergy Asthma Proc; 2018 Mar; 39(2):127-135. PubMed ID: 29208079
[TBL] [Abstract][Full Text] [Related]
5. Real-World Effectiveness of Omalizumab in Severe Allergic Asthma: A Meta-Analysis of Observational Studies.
Bousquet J; Humbert M; Gibson PG; Kostikas K; Jaumont X; Pfister P; Nissen F
J Allergy Clin Immunol Pract; 2021 Jul; 9(7):2702-2714. PubMed ID: 33486142
[TBL] [Abstract][Full Text] [Related]
6. Impact of Omalizumab in Patients with Severe Uncontrolled Asthma and Possible Predictive Biomarkers of Response: A Real-Life Study.
Rojo-Tolosa S; González-Gutiérrez MV; Sánchez-Martínez JA; Jiménez-Gálvez G; Pineda-Lancheros LE; Gálvez-Navas JM; Jiménez-Morales A; Pérez-Ramírez C; Morales-García C
Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839845
[TBL] [Abstract][Full Text] [Related]
7. Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety.
Mansur AH; Srivastava S; Mitchell V; Sullivan J; Kasujee I
Respir Med; 2017 Mar; 124():36-43. PubMed ID: 28284319
[TBL] [Abstract][Full Text] [Related]
8. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
[TBL] [Abstract][Full Text] [Related]
9. Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia.
Torres-Duque CA; Ocampo-Gómez J; Castillo MM; Cano-Rosales D; Giraldo-Montoya Á; Rodríguez F; Palacios-Ortega I; Durán-Silva M; Reynales H; García E;
BMC Pulm Med; 2022 Nov; 22(1):447. PubMed ID: 36437461
[TBL] [Abstract][Full Text] [Related]
10. [Preliminary clinical observation of omalizumab therapy for moderate to severe asthma].
Wu PH; Dong C; Xie JX; Zhang XX; Liu J; Ouyang M; Ma JJ; Huang WH; Ou CX; Li J; Zhang QL
Zhonghua Jie He He Hu Xi Za Zhi; 2021 Jul; 44(7):611-618. PubMed ID: 34256447
[No Abstract] [Full Text] [Related]
11. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
Carpagnano GE; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Quarato CMI; Foschino Barbaro MP
Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
[TBL] [Abstract][Full Text] [Related]
12. Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study).
Niven RM; Saralaya D; Chaudhuri R; Masoli M; Clifton I; Mansur AH; Hacking V; McLain-Smith S; Menzies-Gow A
BMJ Open; 2016 Aug; 6(8):e011857. PubMed ID: 27507234
[TBL] [Abstract][Full Text] [Related]
13. Does omalizumab make a difference to the real-life treatment of asthma exacerbations?: Results from a large cohort of patients with severe uncontrolled asthma.
Grimaldi-Bensouda L; Zureik M; Aubier M; Humbert M; Levy J; Benichou J; Molimard M; Abenhaim L;
Chest; 2013 Feb; 143(2):398-405. PubMed ID: 23505637
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of omalizumab in real world uncontrolled allergic asthma patients.
Arrobas A; Barbosa MP; Rabiais S; Vandewalle B; Félix J
Pulmonology; 2021; 27(2):124-133. PubMed ID: 32247710
[TBL] [Abstract][Full Text] [Related]
15. Profile of patients treated with omalizumab in routine clinical practice in Spain.
Ancochea J; Chivato T; Casan P; Picado C; Herráez L; Casafont J
Allergol Immunopathol (Madr); 2014; 42(2):102-8. PubMed ID: 23267505
[TBL] [Abstract][Full Text] [Related]
16. Response to omalizumab in patients with severe allergic asthma: A real-life study.
Zierau L; Walsted ES; Thomsen SF; Backer V
Respir Med; 2017 Oct; 131():109-113. PubMed ID: 28947015
[TBL] [Abstract][Full Text] [Related]
17. Omalizumab lowers asthma exacerbations, oral corticosteroid intake and blood eosinophils: Results of a 5-YEAR single-centre observational study.
Pelaia C; Calabrese C; Barbuto S; Busceti MT; Preianò M; Gallelli L; Savino R; Vatrella A; Pelaia G
Pulm Pharmacol Ther; 2019 Feb; 54():25-30. PubMed ID: 30414440
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of Omalizumab in Severe Allergic Asthma and Nasal Polyposis: A Real-Life Study.
Tiotiu A; Oster JP; Roux PR; Nguyen Thi PL; Peiffer G; Bonniaud P; Dalphin JC; de Blay F
J Investig Allergol Clin Immunol; 2020; 30(1):49-57. PubMed ID: 30931917
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the clinical features and laboratory data of patients with severe asthma classified as super-responder or non super-responder to omalizumab treatment: a single-center real-life study.
Cakmak ME; Öztop N; Yeğit OO; Özdedeoğlu Ö
J Asthma; 2023 Oct; 60(10):1862-1868. PubMed ID: 36971065
[TBL] [Abstract][Full Text] [Related]
20. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal.
Burch J; Griffin S; McKenna C; Walker S; Paton J; Wright K; Woolacott N
Pharmacoeconomics; 2012 Nov; 30(11):991-1004. PubMed ID: 22950547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
